Mochida Pharmaceutical Co., Ltd. · TSE:4534
Mochida Pharmaceutical — Q2 FY2025 Earnings Presentation
28 slides from Mochida Pharmaceutical's earnings presentation, Nov 7, 2025
Slide 1: FY2025 Q2 Financial Results Presentation
FY2025 Q2 Financial Results Presentation (From April 1, 2025 to September 30, 2025) November 7, 2025 Mochida Pharmaceutical Co., Ltd.
Slide 2: Agenda
Agenda • FY2025 Q2 Overview • FY2025 Forecast • Progress on the Development • Strategic Investment: Capital Participation in And Pharma Co., Ltd. FY2025 Q2 Financial Results Presentation 2
Slide 3: FY2025 Q2 Overview
FY2025 Q2 Overview FY2025 Q2 Financial Results Presentation 3
Slide 4: Summary of FY2025 Q2 (1/2)
Summary of FY2025 Q2 (1/2) Consolidated Financial Results Increase in Net sales Increase in Operating profits Net sales increased due to Operating profits increased due to an increase the growth of new drugs. in gross profit resulting from higher net sales in pharmaceutical business. (Billions of
Slide 5: Summary of FY2025 Q2 (2/2)
Summary of FY2025 Q2 (2/2) Launch • Omvoh Subcutaneous Injection Autoinjectors/Syringes 200mg（additional dosage form） • Lialda Tablets 600mg（additional dosage form） Progress in Development Pipeline • Obtained approval for the addition of dosage and administration of Lialda for pediatric patients
Slide 6: Consolidated Operating Results in FY2025 Q2
Consolidated Operating Results in FY2025 Q2 （Millions of yen） FY2024 Q2 FY2025 Q2 Y o Y change (Y o Y change) (Y o Y change) 51,096 54,985 Net sales 3,888 (3.3％) (7.6%) 3,793 4,967 Operating profit 1,174 (-4.0％) (31.0%) Ratio of operating 7.4% 9.0% 1.6 points profit to net sales 4,079 5,179 Ordinary
Slide 7: Net Sales by Business in FY2025 Q2
Net Sales by Business in FY2025 Q2 (Millions of yen) FY2024 Q2 FY2025 Q2 Y o Y change (Y o Y change) (Y o Y change) 51,096 54,985 Net sales 3,888 (3.3％) (7.6%) Pharmaceutical 47,555 51,058 business 3,502 (2.7％) (7.4%) Healthcare 3,540 3,926 business 386 (11.0％) (10.9%) FY2025 Q2 Financial Results Pr
Slide 8: Sales of Major Products in FY2025 Q2 (1/2)
Sales of Major Products in FY2025 Q2 (1/2) （Billions of yen） FY2025 Q2 Products FY2024 Q2 YoY Sales Value Ratio ■ New drugs Treatment of ulcerative colitis Lialda 7.4 8.0 0.5 7% Treatment for chronic Goofice*1 4.1 4.4 0.3 8% constipation Treatment for chronic Movicol 3.2 3.5 0.3 11% constipation Tre
Slide 9: Sales of Major Products in FY2025 Q2 (2/2)
Sales of Major Products in FY2025 Q2 (2/2) （Billions of yen） FY2025 Q2 Products FY2024 Q2 YoY Sales Value Ratio ■ Long-listed products Drug for hyperlipidemia and arteriosclerosis obliterans Epadel 2.9 2.2 -0.6 -22% Heparin Anticoagulant agent Sodium 0.6 0.6 0.0 3% MOCHIDA ■ Generic Drugs (including
Slide 10: Consolidated Financial Statements
Consolidated Financial Statements （Millions of yen） Major fluctuation factors （Millions of yen） FY2024 FY2025 Q2 YoY （As of Mar. 31, 2025） （As of Sep. 30, 2025） change Y o Y change Total assets 160,121 165,721 5,599 Cash and deposits 4,567 Total current Accounts receivable - trade 1,284 assets 119,6
Slide 11: Shareholder Returns
Shareholder Returns Maintaining a stable dividends while enhancing internal reserves for future business development Policy Maintaining the dividend of at least 80 yen per share during the 25-27 Medium-term Management Plan （Yen） FY2024 FY2025 Annual dividends per 80.00 80.00（Forecast） share （int
Slide 12: FY2025 Forecast
FY2025 Forecast FY2025 Q2 Financial Results Presentation 12
Slide 13: Prospects for FY2025
Prospects for FY2025 Pharmaceutical Business • Maximizing the product value of new drugs Expanding treatment agents of Inflammatory Bowel Disease by focusing on the gastroenterology Further growth of Goofice, Urece and Treprost • Further value enhancement of High Purity EPA formulation and Die
Slide 14: Consolidated Financial Result Forecasts
Consolidated Financial Result Forecasts （Millions of yen） FY2024 FY2025 Forecasts （Y o Y change） （Y o Y change） 105,159 110,500 Net sales (2.2％) (5.1％) 8,126 7,000 Operating profit (40.1％) (-13.9％) Ratio of operating 7.7％ 6.3％ profit to net sales 8,067 7,500 Ordinary profit (33.6％) (-7.0％) Profit at
Slide 15: Forecasts by Business
Forecasts by Business （Millions of yen） FY2024 FY2025 Forecasts (Y o Y change) (Y o Y change) 105,159 110,500 Net sales (2.2％) (5.1％) Pharmaceutical 97,989 103,000 business (1.6％) (5.2％) Healthcare 7,169 7,400 business (11.5％) (3.9％) FY2025 Q2 Financial Results Presentation 15
Slide 16: Forecasts of Major Products (1/2)
Forecasts of Major Products (1/2) （Billions of yen） FY2025 Forecasts Products FY2024 YoY Sales Value Ratio ■ New drugs Treatment of ulcerative colitis Lialda 15.1 16.0 0.8 5% Treatment for chronic Goofice*1 8.3 9.0 0.6 8% constipation Treatment for chronic Movicol 6.6 6.6 0.0 0% constipation Treatme
Slide 17: Forecasts of Major Products (2/2)
Forecasts of Major Products (2/2) （Billions of yen） FY2025 Forecasts Products FY2024 YoY Sales Value Ratio ■ Long-listed products Drug for hyperlipidemia and arteriosclerosis obliterans Epadel 4.8 4.3 -0.5 -12% Heparin Anticoagulant agent Sodium 1.3 1.3 -0.0 -2% MOCHIDA ■ Generic Drugs (including Bi
Slide 18: Progress on the Development
Progress on the Development FY2025 Q2 Financial Results Presentation 18
Slide 19: Development Pipeline: Ethical drugs
Development Pipeline: Ethical drugs Development code Stage Remarks Indications <Generic name> Phase Ⅱ Phase Ⅲ Filed Approved ＜Development country＞ Licensed-in from Takeda Pharmaceuticals MD-0901* Ulcerative colitis U.S.A., Inc. <mesalazine> (pediatric indication) In-house development <Japan> Biosimi
Slide 20: Development Pipeline: Medical devices
Development Pipeline: Medical devices Stage Development code Intended use Remarks Therapeutic Therapeutic [Product name] or indications ＜Development country＞ exploratory confirmatory Filed Approved study study dMD-001* Articular cartilage In-house development [Cartilage Repair Device Mochi-Gel] lesi
Slide 21: Strategic Investment: Capital Participation in And Pharma Co., Ltd.
Strategic Investment: Capital Participation in And Pharma Co., Ltd. FY2025 Q2 Financial Results Presentation 21
Slide 22: Overview of Capital Participation in And Pharma Co., Ltd.
Overview of Capital Participation in And Pharma Co., Ltd. Acquired 20% of And Pharma’s shares and made And Pharma an equity-method affiliate（Effective October 1, 2025） Transaction Structure Main • Joint development and stable supply of 1. And Pharma conducts a third-party allocation of shares Collab
Slide 23: Expected Business Synergies and Collaborative Effects
Expected Business Synergies and Collaborative Effects Establishment of a domestic biosimilar supply system utilizing the extensive biosimilar expertise held by our company and the manufacturing capabilities of And Pharma’s subsidiaries Establishment of an efficient manufacturing and supply system th
Slide 24: Positioning in the 25-27 Medium-term Management Plan
Positioning in the 25-27 Medium-term Management Plan This acquisition of shares is positioned as a concrete measure to provide medical economic value through generics and biosimilars under “Strengthening the Profitability of Core Businesses.” Strengthening the Profitability Continued Investment of C
Slide 25: Impact on Earnings and Progress
Impact on Earnings and Progress The contribution to our earnings through equity method investment income will be recognized from the third quarter of the fiscal year ending March 2026. • The impact amount on our earnings for the fiscal year ending March 2026 is currently under review. Dispatched
Slide 26: FY2025 Q2 Financial Results Presentation
FY2025 Q2 Financial Results Presentation 26
Slide 27: Disclaimer (1/2)
Disclaimer (1/2) This material is an English translation of the Financial Results Presentation for the Fiscal Year 2025 Q2 to be issued on November 7, 2025 in Japanese, and the Japanese presentation is given priority regarding content and interpretation. The information provided in this material
Slide 28: Disclaimer (2/2)
Disclaimer (2/2) Approved products contain risks relating to manufacturing and marketing which include, but not are limited to, situations in which the Company may face deficiencies in manufacturing capacity needed to meet demand, difficulties in securing the supplies of raw materials, and demand
Mochida Pharmaceutical — Q2 FY2025 Earnings Presentation on 6ix